Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Jan;141(1):32-9.
doi: 10.1016/j.pharmthera.2013.08.002. Epub 2013 Aug 19.

Microbiota abnormalities in inflammatory airway diseases - Potential for therapy

Affiliations
Review

Microbiota abnormalities in inflammatory airway diseases - Potential for therapy

Eva S Gollwitzer et al. Pharmacol Ther. 2014 Jan.

Abstract

Increasingly the development of novel therapeutic strategies is taking into consideration the contribution of the intestinal microbiota to health and disease. Dysbiosis of the microbial communities colonizing the human intestinal tract has been described for a variety of chronic diseases, such as inflammatory bowel disease, obesity and asthma. In particular, reduction of several so-called probiotic species including Lactobacilli and Bifidobacteria that are generally considered to be beneficial, as well as an outgrowth of potentially pathogenic bacteria is often reported. Thus a tempting therapeutic approach is to shape the constituents of the microbiota in an attempt to restore the microbial balance towards the growth of 'health-promoting' bacterial species. A twist to this scenario is the recent discovery that the respiratory tract also harbors a microbiota under steady-state conditions. Investigators have shown that the microbial composition of the airway flora is different between healthy lungs and those with chronic lung diseases, such as asthma, chronic obstructive pulmonary disease as well as cystic fibrosis. This is an emerging field, and thus far there is very limited data showing a direct contribution of the airway microbiota to the onset and progression of disease. However, should future studies provide such evidence, the airway microbiota might soon join the intestinal microbiota as a target for therapeutic intervention. In this review, we highlight the major advances that have been made describing the microbiota in chronic lung disease and discuss current and future approaches concerning manipulation of the microbiota for the treatment and prevention of disease.

Keywords: Airways; BOS; CF; COPD; Chronic lung disease; FMT; IBD; Intestinal tract; Microbiome; Microbiota; Probiotics; bronchiolitis obliterans syndrome; chronic obstructive pulmonary disease; cystic fibrosis; fecal microbiota transplantation; inflammatory bowel disease.

PubMed Disclaimer

Publication types

LinkOut - more resources